Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.
The antiviral remdesivir should not be used as a routine treatment for Covid-19 patients in critical care wards, the head of one of the world’s top bodies representing intensive care doctors said, in a blow to the drug developed by U.S. firm Gilead.
As the world waits with bated breath for a treatment for COVID-19, all eyes are on Gilead Science’s antiviral drug remdesivir as a potential candidate.
Renaissance genius Leonardo da Vinci’s litany of exquisite but unfinished work shows he probably had an attention disorder common to modern society.
